Overview

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Status:
Terminated

Trial end date:
2017-03-06

Target enrollment:

Participant gender:

Summary

A long-term extension study to assess the safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) in children with inherited mitochondrial diseases who previously enrolled into study RP103-MITO-001 (NCT02023866).

Phase:

Phase 2

Details

Lead Sponsor:

Horizon Pharma USA, Inc.
Raptor Pharmaceuticals Inc.

Treatments:

Cysteamine